Cost-Effectiveness Analysis of Initiating Type 2 Diabetes Therapy with a Sodium-Glucose Cotransporter 2 Inhibitor Versus Conventional Therapy in Japan.

Ataru IgarashiKeiko Maruyama-SakuraiAnna KubotaHiroki AkiyamaToshitaka YajimaShun KohsakaHiroaki Miyata

Published in: Diabetes therapy : research, treatment and education of diabetes and related disorders (2022)

Our results suggest that initiating T2DM treatment with SGLT2i, aimed at managing cardiovascular and renal complications from the early stages of diabetes, can improve the clinical outcome and reduce cost burden of T2DM.

Keyphrases

type diabetes
glycemic control
cardiovascular disease
risk factors
insulin resistance
metabolic syndrome
skeletal muscle